Taxpayers are bankrolling the development of a male birth control pill designed to be popped 30 minutes before sex — another pharmaceutical intervention into human reproduction at a moment when Western fertility is in free fall and the family unit is under sustained pressure.
Pharmacologists Dr. Jochen Buck and Dr. Lonny Levin at Weill Cornell Medicine have received a multimillion-dollar grant from the National Institute of Child Health and Human Development to begin human safety trials on their experimental contraceptive, according to Newsweek. The four-year award is the third government grant the pair has pulled down since 2020. The pill works by inhibiting an enzyme called soluble adenylyl cyclase, or sAC, which is essential for sperm motility. Take the pill, the sperm stop swimming for six to eight hours, then fertility supposedly returns to normal.
Buck told Newsweek the inhibitor "keeps the enzyme off even after the sperm are ejaculated into the woman," meaning those sperm cannot travel deep enough to fertilize an egg. Levin framed it simply: without the enzyme, "men are infertile because while they ejaculate normally, their sperm do not travel."
The institutional pitch is familiar. Newsweek leaned heavily on the burden-sharing argument, quoting Yale associate professor Jean-Ju Chung, who said roughly a third of women abandon hormonal contraceptives within the first year due to side effects. "We need options that act before fertilization, that do not ask a healthy person to take hormones continuously, and that let men share the responsibility," Chung said. The CDC data point — 40 percent of U.S. pregnancies are unplanned — was presented as the moral imperative for yet another pharmaceutical fix.
What neither the researchers nor the coverage grappled with is the landscape into which this pill would arrive. The United States fertility rate sits at roughly 1.66 births per woman, well below replacement level of 2.1. The family structure that built and sustained this country is fraying — and the pharmaceutical industry, having spent decades disrupting women's hormonal systems with contraceptives whose side effects Chung herself catalogs, now eyes men as its next market.
Follow the money: the National Institute of Child Health and Human Development is funding research to suppress child creation. The industry that profited from the Pill, from hormonal IUDs, from decades of female hormonal disruption now stands to profit again by selling men a pre-sex fertility kill switch. Buck and Levin called it "extremely gratifying" to receive the grant, noting that few such awards are given and that peer review validated their work.
The clinical trials will test whether the pill is safe. Whether the broader project — chemically neutering both sexes while birth rates crater — is wise received no peer review at all.
The open question is not whether this pill works. It is who benefits when a society that cannot replace itself keeps paying to make itself more sterile.
